2017 Cardiovascular Research Day Abstract Book

Recommendations

Info

79 Serum Levels of Dioxin-Like Pollutants Are Positively Associated With the Cardiometabolic Disease Risk Biomarker TMAO in Leaner Individuals Michael Petriello, PhD 1 • Richard Charnigo • Manjula Sunkara • Sony Soman • Marian Pavuk 2 • Linda Birnbaum 3 • Andrew Morris, PhD 4 • Bernhard Hennig 5 1Cardiovascular Research Center, University of Kentucky • 2 CDC Agency for Toxic Substances and Disease Registry • 3 NCI at NIEHS • 4 Cardiovascular Medicine, University of Kentucky • 5 Superfund Research Center, University of Kentucky Postdoc Trimethylamine N-oxide (TMAO) is a diet and gut microbiota-derived metabolite that has been linked to cardiovascular disease risk in human studies and animal models. TMAO levels show wide inter and intra individual variability in humans that can likely be accounted for by multiple factors including diet, the gut microbiota, levels of the TMAO generating liver enzyme Flavin-containing monooxygenase 3 (FMO3) and kidney function. We recently found that dioxin-like (DL) environmental pollutants increased FMO3 expression to elevate circulating diet-derived TMAO in mice, suggesting that exposure to this class of pollutants might also contribute to inter-individual variability in circulating TMAO levels in humans. To begin to explore this possibility we examined the relationship between body burden of DL pollutants (reported by serum lipid concentrations) and serum TMAO levels (n=340) in the Anniston, AL cohort, which was highly exposed to polychlorinated biphenyls (PCBs). TMAO concentrations in archived serum samples from the Anniston Community Health Survey (ACHS-II) were measured, and associations of TMAO with 28 indices of pollutant body burden, including total dioxins toxic equivalent (TEQ), were quantified. Twenty-three (22 after adjustment for multiple comparisons) of the 28 indices were significantly positively associated with TMAO. Multivariate modeling revealed that total dioxins TEQ was significantly associated with TMAO among females (except at high BMIs) but not among males. Our results from this cross-sectional study indicate that exposure to DL pollutants may contribute to elevated serum TMAO levels. With the observation that dioxins were only associated with TMAO in leaner individuals, we have begun to mechanistically study the relationship between dioxin exposure, FMO3/TMAO, and cardiometabolic disease by characterizing a mouse model that develops atherosclerosis but not adipose tissue expansion. We examined the effects of PCB 126 on markers of systemic inflammation and atherosclerotic lesion size. Exposed mice exhibited significantly increased plasma cytokine levels and accelerated atherosclerotic lesion formation. More work needs to be completed to determine the role of TMAO and FMO3 in these processes (Supported in part by NIEHS/NIH grant P42ES007380). 95
80 Insulin signaling regulates apolipoprotein (Apo) AI secretion from hepatocytes Ailing Ji, PhD 1 • Xuebing Wang 1 • Lisa Bennett 2 • David Graf 2 • Gregory Graf, PhD 2 • Deneys van der Westhuyzen, PhD 1 1Cardiovascular Research Center, University of Kentucky • 2 Pharmaceutical Sciences, University of Kentucky Staff Insulin resistance is associated with increased risk for cholesterol gallstones as well as the development of diabetic dyslipidemia in which plasma levels of HDL cholesterol are reduced. HDL is the primary cholesterol carrier in the reverse cholesterol transport (RCT) pathway, the process by cholesterol is delivered from peripheral organs to the liver for elimination in the bile. Therefore, we hypothesized that insulin signaling is a regulator of hepatobiliary cholesterol clearance from the plasma and secretion into bile. To directly test the role of insulin signaling, we utilized mice harboring insulin receptor flanked by loxP sites (IRfl/fl) in combination with adenoassociated viral vectors containing no transgene (empty) or Cre recombinase to generate control and liver insulin receptor knock out mice (LIRKO), respectively. As with previous LIRKO strains (albumin-Cre, adenoviral-Cre), LIRKO mice showed markedly reduced insulin receptor mRNA and protein in liver, but not skeletal muscle or adipose tissue as well as impaired glucose tolerance when compared to controls. LIRKO mice had increased biliary cholesterol secretion as well as increased expression of the ABCG5 ABCG8 sterol transporter, the primary mediator of biliary cholesterol secretion. Levels of SR-BI, the primary HDL receptor were unchanged as were rates of HDL clearance from plasma and selective delivery of HDL cholesterol to the liver. None-the-less, plasma HDL cholesterol and ApoAI were reduced. Despite these reductions, ApoAI protein, but not mRNA, was increased in the liver of LIRKO mice. Immunofluorescence microscopy revealed that ApoAI accumulated in membrane-bound inclusions that stained positively for markers of early, late and recycling endosomes and of lysosomes. These structures persisted in primary hepatocyte cultures where rates of ApoAI secretion into the culture medium were reduced. To determine the intracellular itinerary of ApoAI, we developed a chimera of mCherry fluorescent protein and human ApoAI. mCherry ApoAI was capable of forming nascent HDL, associated with HDL in plasma, and partially restored HDL cholesterol in ApoAI-deficient mice. However, this mCherry-ApaAI failed to colocalize with a probe for acidic compartments in live cells, suggesting that the compartment is unique or that the accumulation of ApoAI neutralizes the endosomal/lysosomal vesicles in which it accumulates. Additional studies will be required to investigate the route by which ApoAI arrives and accumulates in cells with impaired insulin signaling. 96
Page 1 and 2:
Cardiovascular Research Day ABSTRAC
Page 3 and 4:
SCHEDULE FOR THE DAY Friday, Novemb
Page 5 and 6:
SCHEDULE FOR THE DAY continued Frid
Page 7 and 8:
2017 GILL HEART INSTITUTE YOUNG INV
Page 9 and 10:
FEATURED SPEAKER Calum MacRae, M.D.
Page 11 and 12:
SPECIAL PRESENTATION Mark Stoops He
Page 13 and 14:
NOTES 12
Page 15 and 16:
2017 POSTER PARTICIPANTS 40 Mohamed
Page 17 and 18:
2017 ABSTRACTS 16
Page 19 and 20:
2 Inhibition of Megalin Reduces Ath
Page 21 and 22:
4 Identification of a Lipid Signatu
Page 23 and 24:
6 Serum Amyloid A Activates the NLR
Page 25 and 26:
8 Azithromycin Therapy Reduces Card
Page 27 and 28:
10 Evidence of Angiotensin II-depen
Page 29 and 30:
12 Auditory Entrainment of Respirat
Page 31 and 32:
14 Cardiac specific Rad knockout In
Page 33 and 34:
16 Hypercholesterolemia Induces Acu
Page 35 and 36:
18 A Novel Approach for Modifying I
Page 37 and 38:
20 Clinical Use of the Amplatzer Se
Page 39 and 40:
22 Regulation of Akt Signaling by N
Page 41 and 42:
24 Vascular Inflammatory Regulation
Page 43 and 44:
26 Vascular inflammation induced ex
Page 45 and 46: 28 Sexual Dimorphism of Angiotensin
Page 47 and 48: 30 Computational modeling of amylin
Page 49 and 50: 32 PCB 126 Exposure Increases Perip
Page 51 and 52: 34 Endothelial Mineralocorticoid Re
Page 53 and 54: 36 Optimization of immunomagnetic s
Page 55 and 56: 38 Gestational Diabetes Provokes Po
Page 57 and 58: 40 The Prognostic Role of Elevated
Page 59 and 60: 42 Lysophosphatidic Acid Receptor 4
Page 61 and 62: 44 Recapitulating In Vivo Fibroblas
Page 63 and 64: 46 Sex-Specific Differences in Card
Page 65 and 66: 48 Ticagrelor Reduces Inflammation
Page 67 and 68: 50 Association between Plasma Chole
Page 69 and 70: 52 Does Light Pollution Affect the
Page 71 and 72: 54 Impact of miR-33 antagonism on m
Page 73 and 74: 56 Isolation and characterization o
Page 75 and 76: 58 The XY sex chromosome complement
Page 77 and 78: 60 CHROME: a Long Non-coding RNA th
Page 79 and 80: 62 Making Good: Secretory Quality C
Page 81 and 82: 64 Thrombospondin 1 (TSP1) Deficien
Page 83 and 84: 66 Serum Amyloid A3 is a High Densi
Page 85 and 86: 68 Adipocyte deficiency of ACE2 inc
Page 87 and 88: 70 Hypercholesterolemia-induced end
Page 89 and 90: 72 Increased Circulating Trimethyla
Page 91 and 92: 74 Circulating Bacterial Small RNA
Page 93 and 94: 76 Pancreatic Beta Cell Export of m
Page 95: 78 Understanding inhibition of lipo
Page 99 and 100: 82 Protease-activated Receptor 2 De
Page 101 and 102: 84 Reduced Low-Density Lipoprotein
Page 103 and 104: 86 Pharmacological inhibition of Hu
Page 105 and 106: 88 The Effects of Hypercholesterole
Page 107 and 108: 90 Reduced HDL in mice overexpressi
Page 109 and 110: 92 Human Antigen R (HuR) Regulates
Page 111 and 112: 94 Impact of miR-33 antagonism on c
Page 113 and 114: 96 HB-EGF is a Key Positive Regulat
Page 115 and 116: 98 HDL-miR-223 Communication Pathwa
Page 117 and 118: 100 Short-Term Exercise Training Di
Page 119 and 120: 102 The Ral-Exocyst Pathway Regulat
Page 121 and 122: NOTES 120
show all

2017 Cardiovascular Research Day Abstract Book

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?